ADA 2019 Standards of Care Emphasize Patient-Centered Care
Updates include use of SGLT-2 inhibitors and GLP-1 receptor agonists for T2DM, CVD; endorsed by ACC
Sorafenib for Desmoid Tumors Ups Progression-Free Survival
Two-year progression-free survival rate 81 percent with sorafenib vs. 36 percent with placebo
Global Lifetime Risk for Stroke About 25 Percent in 2016
Estimated risk from age 25 years onward is 24.9 percent, with geographic variation in risk
Exposure to Metals, Pesticides Tied to CVD in Hispanics/Latinos
Prevalence ratio for any cardiovascular disease was 2.18 for those working with pesticides
Structured Family-Centered Peds Rounds Improve Patient Safety
Forty percent decrease seen in harmful errors; decrease also in nonpreventable adverse events
Pembrolizumab Promising for Metastatic Head, Neck SCC
Prolongs survival among patients with recurrent, metastatic head and neck squamous cell carcinoma
Hospitalization for Upper GI Bleed Highest With Rivaroxaban
Upper gastrointestinal bleeding hospitalization risk lower for anticoagulant tx with PPI cotherapy
Overlapping Orthopedic Surgery Noninferior for Patient Safety
Reduced odds of perioperative complications seen for overlapping surgery versus nonoverlapping surgery
Restrictive, Obstructive Lung Disease Linked to Dementia Risk
Associations seen for both Alzheimer's disease-related dementia and cerebrovascular etiologies
FDA Advisory Panels: Prescribe Naloxone With Opioid Painkillers
Federal government urged to make naloxone more widely available, easier to obtain, and cheaper
